Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell 3000 Index (the Index). The fund trailed the benchmark due to stock selection and, to a lesser extent, active sub-industry weights. In addition, please check the fund’s top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as RadNet, Inc. (NASDAQ:RDNT). Headquartered in Los Angeles, California, RadNet, Inc. (NASDAQ:RDNT) provides outpatient diagnostic imaging services. One-month return of RadNet, Inc. (NASDAQ:RDNT) was 4.36%, and its shares gained 0.04% of their value over the last 52 weeks. On May 9, 2025, RadNet, Inc. (NASDAQ:RDNT) stock closed at $55.74 per share with a market capitalization of $4.181 billion. Baron Health Care Fund stated the following regarding RadNet, Inc. (NASDAQ:RDNT) in its Q1 2025 investor letter: "Higher exposure to lagging life sciences tools & services stocks and poor stock selection in health care services and managed health care were other material detractors in the period. The Fund’s only position in health care services, diagnostic imaging services provider RadNet, Inc. (NASDAQ:RDNT), weighed on performance after reporting below consensus guidance for fiscal year 2025. We view the reasons for the lower guidance as non-recurring and remain excited about the optionality embedded in RadNet’s AI products, which provide enhanced digital image reading and analysis, boosting radiologists’ accuracy and efficiency."RadNet, Inc. (RDNT): “Let’s Take a Pass” Says Jim Cramer A radiologist studying a monitor with a detailed image of a lung cancer tumor. RadNet, Inc. (NASDAQ:RDNT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held RadNet, Inc. (NASDAQ:RDNT) at the end of the fourth quarter which was 20 in the previous quarter. In the fourth quarter, RadNet, Inc.’s (NASDAQ:RDNT) revenue increased 13.5% to $477.1 million and adjusted EBITDA increased 14% from Q4 2023 to $75 million. While we acknowledge the potential of RadNet, Inc. (NASDAQ:RDNT) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. Story Continues In another article, we covered RadNet, Inc. (NASDAQ:RDNT) and shared top performing stocks of the last 20 years listed by Jim Cramer. ClearBridge SMid Cap Strategy invested in RadNet, Inc. (NASDAQ:RDNT) during Q4 2024, recognizing its promising growth potential. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. View Comments
RadNet (RDNT) Fell on Lower Than Expected Guidance
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...